It is also worth noting that Lilly's original full-year revenue guidance was for $41 billion, so it handily surpassed that. GLP-1 drugs still lead the way for Eli Lilly Turning to its GLP-1 drugs ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment ...

Butler University's plans to renovate and expand Clowes Memorial Hall, including the addition of a ballroom space, aim to ...

The basic building block of a portfolio should be ... Another top 10 holding is Eli Lilly, the pharma giant behind the Mounjaro and Zepbound obesity drugs. By the beginning of the next decade ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

On an investment spree with billions of dollars’ worth of projects ongoing globally, Indianapolis-based Eli Lilly and Company ...

Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million ...